Compare REYN & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REYN | SRRK |
|---|---|---|
| Founded | 1947 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.6B |
| IPO Year | 2020 | 2018 |
| Metric | REYN | SRRK |
|---|---|---|
| Price | $23.22 | $46.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $26.75 | ★ $47.88 |
| AVG Volume (30 Days) | 764.4K | ★ 1.4M |
| Earning Date | 02-04-2026 | 11-14-2025 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $3,707,000,000.00 | N/A |
| Revenue This Year | $1.76 | N/A |
| Revenue Next Year | $1.97 | $20,271.77 |
| P/E Ratio | $16.14 | ★ N/A |
| Revenue Growth | ★ 0.71 | N/A |
| 52 Week Low | $20.91 | $22.71 |
| 52 Week High | $28.22 | $48.28 |
| Indicator | REYN | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 36.36 | 62.93 |
| Support Level | $23.89 | $42.61 |
| Resistance Level | $24.70 | $46.38 |
| Average True Range (ATR) | 0.40 | 1.91 |
| MACD | -0.12 | -0.33 |
| Stochastic Oscillator | 10.98 | 57.34 |
Reynolds Consumer Products Inc is a provider of household products. The firm is engaged in the production and sales of cooking products, waste and storage products, and tableware. It operates through four reportable segments namely, Reynolds Cooking and Baking, Hefty Waste and Storage, Hefty Tableware, and Presto Products. Reynolds Cooking and Baking segment produce branded and store brand aluminum foil, disposable aluminum pans, parchment paper, freezer paper, wax paper, butcher paper, plastic wrap, baking cups, oven bags and slow cooker liners.
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.